Rinvoq (upadacitinib) is a Disease Modifying Anti-Rheumatic Drug (DMARD) that's currently used to treat rheumatoid arthritis with and without methotrexate, psoriatic arthritis, and ankylosing spondylitis.
Rinvoq works by suppressing the immune system. It belongs to a class of medications known as Janus Kinase (JAK) inhibitors.
Rinvoq is one of the few therapies for arthritis that is available as an oral tablet. The standard dose is 15 mg taken once every day.
Rinvoq does not work right away. It can take about 2 to 8 weeks before patients start feeling better, and it can take 3 to 6 months to feel the maximum effect of this medication. If the dose is changed, it can take 2-8 weeks to feel the effects.
The manufacturer of Rinvoq offers a support program to Canadian patients that are prescribed the medication:Patient support program enrolment forms